글로벌 인간 마이크로바이옴 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

인간 마이크로바이옴 시장 분석

인간 마이크로바이옴 시장은 전반적인 웰빙에서 장 건강이 차지하는 중요한 역할에 대한 인식이 높아짐에 따라 급속한 성장을 경험하고 있습니다. 이 시장은 마이크로바이옴을 조절하여 건강 결과를 개선하도록 설계된 프로바이오틱스, 프리바이오틱스, 마이크로바이옴 기반 치료제와 같은 제품을 포함합니다. 고급 시퀀싱 기술 및 개인화된 마이크로바이옴 분석을 포함한 최근의 발전은 혁신을 주도하여 맞춤형 식이 요법 및 치료적 개입을 가능하게 합니다. 비만, 당뇨병, 자가면역 질환과 같은 라이프스타일 관련 질병의 증가로 인해 마이크로바이옴 기반 솔루션에 대한 수요가 증가했습니다. 특히 주요 업체는 다양한 건강 상태에서 마이크로바이옴의 역할을 탐구하기 위해 연구 개발에 점점 더 투자하고 있습니다. 소비자가 자연적이고 전체적인 건강 옵션을 추구함에 따라 인간 마이크로바이옴 시장은 상당한 성장을 이룰 준비가 되어 있으며 소비자 및 임상 응용 분야에서 확장이 예상되어 의료 발전 및 투자 기회에 중요한 영역이 되었습니다.

인간 마이크로바이옴 시장 규모

글로벌 인간 마이크로바이옴 시장 규모는 2023년에 9억 549만 달러로 평가되었으며, 2031년까지 46억 1,874만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 22.95%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

인간 마이크로바이옴 시장 동향

“ 생명공학의 발전”

인간 마이크로바이옴 시장은 생명공학의 발전과 건강에 미치는 마이크로바이옴의 영향에 대한 이해 증가로 인해 중요한 추세를 보이고 있습니다. 게놈 시퀀싱과 데이터 분석의 혁신으로 개별 마이크로바이옴에 대한 보다 정확한 분석이 가능해져 개인화된 의학의 길을 열었습니다. 주목할 만한 추세 중 하나는 염증성 장 질환 및 대사 장애와 같은 특정 질병을 표적으로 삼는 마이크로바이옴 기반 치료제 개발에 대한 집중이 높아지고 있다는 것입니다. 기업들은 장 건강을 증진하고 전반적인 웰빙을 개선하는 제품을 만들기 위해 연구에 많은 투자를 하고 있습니다. 장 건강에 대한 소비자의 인식이 계속 높아짐에 따라 프로바이오틱스와 식이 보충제를 포함한 마이크로바이옴 관련 제품 시장이 확대되고 있으며, 이는 예방적 건강 관리와 웰빙에 대한 전체론적 접근 방식으로의 전환을 반영합니다.

보고서 범위 및 인간 마이크로바이옴 시장 세분화

인간 마이크로바이옴 시장 정의

The human microbiome refers to the diverse community of microorganisms, including bacteria, viruses, fungi, and archaea, that inhabit various sites in the human body, predominantly in the gut. These microbial communities play a crucial role in maintaining health by aiding in digestion, synthesizing essential vitamins, and regulating the immune system. The composition of the microbiome can vary significantly among individuals and is influenced by factors such as diet, lifestyle, age, and environment. A balanced microbiome is essential for overall well-being, while dysbiosis, or an imbalance in microbial populations, has been linked to various health issues, including obesity, diabetes, autoimmune disorders, and gastrointestinal diseases. Research into the human microbiome continues to uncover its complex interactions with the host, highlighting its significance in health and disease management.

Human Microbiome Market Dynamics

Drivers

• Increasing Awareness of Gut Health

The increasing consumer awareness regarding gut health and its significant impact on overall well-being is a major driver for the human microbiome market. As individuals become more informed about the role of gut microbiota in various health outcomes—ranging from digestion and immunity to mental health—there has been a marked rise in the demand for microbiome-related products, including probiotics and dietary supplements. This awareness is further fueled by research highlighting the intricate relationship between gut health and chronic diseases, prompting consumers to seek preventative measures. Consequently, companies are responding by developing innovative products that cater to this growing interest, ultimately contributing to the expansion of the human microbiome market. Enhanced marketing efforts and educational campaigns are also pivotal in shaping consumer perceptions, further driving demand.

• Rising Incidence of Chronic Diseases

The rising prevalence of chronic diseases, such as obesity, diabetes, and various gastrointestinal disorders, significantly drives the demand for microbiome-based therapies and interventions. As these conditions become more widespread, healthcare providers and patients alike are seeking effective solutions that target the underlying imbalances in the gut microbiome. Research has demonstrated a strong link between gut health and the management of these chronic illnesses, leading to a growing interest in microbiome modulation as a therapeutic approach. Innovative treatments that leverage probiotics, prebiotics, and other microbiome-targeting strategies are increasingly recognized for their potential to improve health outcomes and enhance quality of life. As a result, the human microbiome market is poised for growth, with companies investing in research and development to create effective therapies that cater to the rising demand for chronic disease management.

Opportunities

• Advancements in Personalized Medicine

Advancements in genomics and microbiome analysis are revolutionizing the development of personalized therapies that cater to individual microbiome profiles. By leveraging cutting-edge sequencing technologies and bioinformatics, researchers can identify specific microbial compositions and their functional implications on health. This tailored approach can lead to more effective treatments for various conditions, including obesity, diabetes, and gastrointestinal disorders. For instance, personalized probiotics or dietary recommendations can be developed based on a patient's unique microbiome, optimizing therapeutic outcomes. As awareness of the microbiome's role in health continues to grow, there is a significant market opportunity for companies to innovate and offer customized solutions that address individual health needs, thus enhancing patient outcomes and fostering market growth.

• Demand for Probiotic and Prebiotic Products Supplements

Growing consumer interest in gut health is significantly driving demand for probiotic and prebiotic supplements. As individuals become more aware of the vital role that gut microbiota play in overall health, they are increasingly seeking products that promote digestive wellness, boost immunity, and improve mental health. This trend presents a lucrative opportunity for companies to capitalize on by developing innovative formulations that cater to specific health needs, such as products targeting gastrointestinal disorders, stress relief, or immune support. Furthermore, incorporating diverse strains of probiotics and natural prebiotics can enhance the efficacy of these supplements, appealing to health-conscious consumers. By aligning product development with consumer preferences and scientific advancements, companies can establish themselves as leaders in the burgeoning gut health market, driving growth and increasing market share.

Restraints/Challenges

• High Research and Development Costs

The financial burden associated with researching and developing microbiome-based therapies is a significant challenge for startups and smaller companies aiming to enter the market. The intricate nature of the human microbiome necessitates extensive research and clinical trials to establish the efficacy and safety of new treatments. This often results in high costs for laboratory testing, personnel, and regulatory compliance. Additionally, securing funding can be difficult for emerging companies, especially when competing against well-established players with more resources. The lengthy timelines required for product development further exacerbate the financial strain, making it challenging for smaller firms to sustain operations and innovate effectively. Consequently, this financial barrier may limit the diversity of products available in the microbiome market and hinder overall market growth.

• Regulatory Requirements

Stringent regulatory requirements for microbiome-based therapies and products present significant challenges that can impede market growth. Regulatory bodies often impose rigorous standards for safety, efficacy, and quality, which can prolong the approval process for new treatments. Companies must navigate a complex landscape of guidelines, requiring extensive documentation, preclinical studies, and clinical trials to demonstrate their products' effectiveness and safety. This exhaustive process demands substantial time and financial resources, potentially discouraging smaller firms and startups from pursuing innovative microbiome solutions. As a result, the lengthy approval timelines can hinder the timely availability of potentially life-changing therapies for patients. Consequently, these regulatory obstacles pose a considerable restraint on the human microbiome market's expansion and innovation.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Human Microbiome Market Scope

The market is segmented on the basis of product, application, disease typeas. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Probiotics
• Prebiotics
• Medical Foods
• Supplements
• Others

Application

• Therapeutics
• Diagnostics

Disease Type

• Obesity
• Diabetes
• Autoimmune Disorder
• Metabolic and Gastrointestinal Disorders
• Cancer
• Other Diseases

 Human Microbiome Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product, application, disease typeas as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the human microbiome market, driven by a robust network of healthcare facilities and increasing investments from major players focused on developing advanced devices. Additionally, the region benefits from a growing number of drug development processes and an uptick in research activities, further solidifying its dominant position. This combination of factors fosters an environment conducive to innovation and growth within the human microbiome sector. Asia-Pacific is projected to experience substantial growth from 2024 to 2031, fueled by government initiatives aimed at raising awareness about health issues. The region is also seeing a surge in medical tourism, increased research activities, and a rise in lifestyle-related diseases and autoimmune disorders. Additionally, the growing demand for high-quality healthcare services further contributes to this upward trend in the market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Human Microbiome Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Human Microbiome Market Leaders Operating in the Market Are:

• ENTEROME (France)
• Yakult U.S.A. Inc. (U.S.)
• DuPont (U.S.)
• Metabiomics (U.S.)
• ViThera Pharmaceuticals, Inc. (U.S.)
• Microbiome Therapeutics Innovation Group (U.S.)
• Vedanta Biosciences, Inc. (U.S.)
• Osel, Inc. (U.S.)
• Merck & Co., Inc. (Germany)
• Seres Therapeutics (U.S.)
• Theriva Biologics, Inc. (U.S.)
• Synlogic (U.S.)
• Qualigen Therapeutics, Inc. (U.S.)
• Symberix, Inc.  (U.S.)
• Symbiotix, LLC. (U.S.)

Latest Developments in Human Microbiome Market

• In July 2023, Infant Bacterial Therapeutics received orphan drug designation from the US FDA for its bacterial product IBP-1016, aimed at treating infants with gastroschisis. This designation supports the development of treatments for rare conditions
• 2023년 12월, MaaT Pharma는 급성 이식편대숙주병(aGvHD) 치료제인 MaaT013의 임상 시험 결과를 발표했습니다. 이 약물은 잘 견디는 안전성 프로필과 81%의 생존율을 보였으며, 잠재적인 효능을 강조했습니다.
• 2023년 7월 MaaT Pharma는 임상 사용을 위한 FDA 승인 마이크로바이옴 치료법의 연구 개발을 발전시키는 데 중점을 둔 조직인 Microbiome Therapeutics Innovation Group에 가입하여 마이크로바이옴 치료 분야에서의 역할을 더욱 강화했습니다.
• 2023년 4월 Finch Therapeutics는 궤양성 대장염 치료를 위한 새로운 미생물 기반 치료법인 CP101을 평가하기 위해 Brigham and Women's Hospital과 임상 시험 계약을 체결하여 해당 질환에 대한 치료 옵션을 발전시키는 것을 목표로 합니다.

SKU-8565